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Abstract This paper is a review of the recommendations
for the prophylaxis of acute emesis induced by moderately
emetogenic chemotherapy as concluded at the third Perugia
Consensus Conference, which took place in June 2009. The
review will focus on new studies appearing since the
Second consensus conference in April 2004. The following
issues will be addressed: dose and schedule of antiemetics,
different groups of antiemetics such as corticosteroids,
serotonin3 receptor antagonists, dopamine2 receptor antag-
onists, and neurokinin1 receptor antagonists. Furthermore,
antiemetic prophylaxis in patients receiving multiple cycles
of moderately emetogenic chemotherapy will be reviewed.
Consensus statements are given, including optimal dose
and schedule of serotonin3 receptor antagonists, dexameth-
asone, and neurokinin1 receptor antagonists. The most
significant recommendations (and changes since the 2004
version of the guidelines) are as follows: the best
prophylaxis in patients receiving moderately emetogenic
chemotherapy (not including a combination of an anthracy-
cline plus cyclophosphamide) is the combination of
palonosetron and dexamethasone on the day of chemother-
apy, followed by dexamethasone on days 2–3. In patients
receiving a combination of an anthracycline plus cyclo-
phosphamide, a combination of a serotonin3 receptor
antagonist plus dexamethasone, plus the neurokinin1
receptor antagonist aprepitant on the day of chemotherapy,
followed by aprepitant days 2–3, is recommended.
Keywords Serotonin antagonists . Neurokinin antagonists .
Dexamethasone . Anthracycline . Cyclophosphamide .
Chemotherapy
Background
In patients receiving moderately emetogenic chemotherapy
(MEC), the most interesting studies in the period from
2004–2009 investigated patients receiving a combination of
an anthracycline plus cyclophosphamide. These cytostatics
are ranked as moderately emetogenic when given as single
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agents, whereas, the combination seems to be as emeto-
genic as cisplatin. A few studies have focused on patients
receiving other kinds of chemotherapy such as oxaliplatin
and irinotecan.
Since the last consensus conference in 2004, three
large and one small phase III study including patients
receiving chemotherapy with a combination of an
anthracycline plus cyclophosphamide, have investigated
the addition of one of the neurokinin1 receptor antago-
nists (aprepitant or casopitant) to the combination of the
serotonin3 receptor antagonist, ondansetron plus dexa-
methasone. Also, a large phase III study comparing
palonosetron with granisetron, both combined with dexa-
methasone, has been published.
Current practice guidelines for prophylaxis of acute
emesis induced by MEC
The Multinational Association of Supportive Care in
Cancer (MASCC), American Society of Clinical Oncology
(ASCO), National Comprehensive Cancer Network
(NCCN), and the European Society of Medical Oncology
(ESMO) practice guidelines for prophylaxis of acute emesis
following MEC are summarized in Table 1. ASCO
published their last update in 2006 [10], as did MASCC
[1]. MASCC does, however, update the recommendations
every 6 months on the website (www.mascc.org). ESMO
publishes an annual update in the Annals of Oncology [6],
and NCCN update their recommendations annually on their
website [13].
The recommendations in Table 1 include the latest
update from journals or websites. All guidelines in 2004
agreed that a 5-hydroxytryptamine type 3 (5-HT3)-receptor
antagonist, in combination with a corticosteroid (dexa-
methasone), was the treatment of choice. An exception
was patients receiving a combination of cyclophospha-
mide plus an anthracycline. For these patients, the addition
of the neurokinin 1 (NK1)-receptor antagonist, aprepitant,
was recommended.
Literature search strategy
Current guidelines references were used as the basis for the
selected references up to year 2004. A Pubmed/Medline
search (from 2004 to 2009, June 1) was conducted of
articles written in English and using the search terms:
“acute emesis” and “chemotherapy” (limited to: humans,
adults, cancer (topic), clinical trial, review, meta-analysis,
practice guideline, and randomized controlled trial). The
abstracts were accessed, and relevant references were
selected by headline and then by abstract. An additional
number of PubMed/Medline searches were completed using
the terms “acute emesis” and using an antiemetic as the
second search term. The antiemetic search terms used
included: ondansetron, granisetron, dolasetron, tropisetron,
ramosetron, azasetron, palonosetron, metoclopramide, pro-
chlorperazine, metopimazine, domperidone, dexametha-
sone, prednisolone, methylprednisolone, prednisone,
benzodiazepines, cannabinoids, aprepitant, and casopitant.
Furthermore, Medline searches, using the term “acute
emesis” and using the chemotherapy agent as the second
search term, were also done. The chemotherapy terms used
included: anthracyclines, doxorubicin, epirubicin, cyclo-
phosphamide, carboplatin, irinotecan, oxaliplatin, and ifos-
famide. All references were reviewed, but primarily, studies
adding new knowledge to the previous guidelines of
MASCC, ESMO, ASCO, and NCCN respectively, were
included in the reference list of this paper. Randomized,
double-blind studies were scored as having the highest
scientific level. (Table 2)
Table 1 Current consensus guideline recommendations for prophylaxis of acute CINV
Group Recommendation MASCC levels of confidence
and consensus
MASCC [4] MEC, not including a combination of an anthracycline plus cyclophosphamide:
5-HT3 receptor antagonist plus dexamethasone.
Level of confidence: high
ASCO [5] Level of consensus: high
ESMO [7] MEC, including a combination of an anthracycline plus cyclophosphamide:
5-HT3 receptor antagonist plus dexamethasone plus aprepitant.
Level of confidence: moderate
Level of consensus: high
NCCN (25) MEC
5-HT3 receptor antagonist plus dexamethasone.
For select patients, e.g. those receiving carboplatin ≥300 mg/m2,
cyclophosphamide ≥600–1,000 mg/m2 and doxorubicin ≥50 mg/m2,
aprepitant or fosaprepitant can be added.
Lorazepam and a H2 blocker or proton pump inhibitor can be
added (or not) in all patients.
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Overview of literature
Studies in patients receiving multiple-day chemotherapy
and studies in patients with refractory emesis or with
breakthrough emesis are not included in this review.
Since the publication of the 2004 guidelines, studies
confirming the optimal dose of the intravenous formulation
of aprepitant, fosaprepitant have been published.
In patients treated with MEC, several phase II and a large
phase III study investigating the 5-HT3-receptor antagonist,
palonosetron, have been published, as have a number of
phase II and phase III studies with the neurokinin1-receptor
antagonists, aprepitant and casopitant (Table 3).
Dose and schedule
Recommended doses of antiemetic agents are given in Table 2.
Except for the dose of dexamethasone (now 8 mg×1 on day 1
of chemotherapy) when given in combination with a NK1
receptor antagonist and the addition of the recommended dose
of fosaprepitant, there are no changes in the recommendations
as compared with the 2004 recommendations.
When oral dexamethasone 20 mg is administered concom-
itantly with oral aprepitant 125 mg, the bioavailability of
dexamethasone (0–24 h) is increased 2.2-fold as compared to
the same dose of dexamethasone without concomitant
aprepitant. To obtain the same bioavailability (0–24 h) when
administered concomitantly with aprepitant, the dose of oral
dexamethasone was decreased to 12 mg on day 1 in phase III
studies [12]. Accordingly, the dose of intravenous methyl-
prednisolone should be reduced one fourth, when adminis-
tered concomitantly with aprepitant [12].
The impact of casopitant on the pharmacokinetics of
dexamethasone also has been investigated [9, 15]. As with
aprepitant, a single dose of oral casopitant 150 mg increases the
bioavailability of oral dexamethasone. The bioavailability of
intravenous dexamethasone is increased by 21% if co-
administered with oral casopitant 150 mg [15]. Because a
randomized study [8] has demonstrated that a single dose of
dexamethasone 8 mg is as good as higher doses, the consensus
panel recommends that a single dose of dexamethasone is used,
also when given in a combination with a neurokinin antagonist.
The recommended oral dose of aprepitant is 125 mg×1,
and the intravenous dose of fosaprepitant is 115 mg×1 [10].
The oral and intravenous doses of casopitant used in phase
III studies were 150 and 90 mg×1, respectively [15].
Corticosteroids
The corticosteroids were described in detail in the last review
paper from the Perugia Consensus Conference in 2004 [4]. As
concluded in 2004, corticosteroids improve the efficacy of
all the serotonin3-receptor antagonists. The inclusion of
dexamethasone in three-drug combinations with a neuro-
kinin1-receptor antagonist will be described later.
No new randomized studies, specifically addressing the
effect of corticosteroids in acute nausea and vomiting
induced by MEC, have been published since the last
update. The recommended doses of dexamethasone as part
of a two-drug combination (serotonin3 receptor antagonist)
and a three-drug combination (serotonin3 receptor antago-
nist plus a neurokinin1-receptor antagonist) are given in the
consensus statement at the end of this paper.
5-HT3 receptor antagonists
The 5-HT3 receptor antagonists ondansetron, granisetron,
dolasetron, tropisetron, and palonosetron were all reviewed
in the previous guidelines. In 2004, there was consensus
5-HT3 receptor antagonists Oral dose Intravenous dose
Ondansetron 8 mg bid or 16 mg qd 8 mg qd
Granisetron 2 mg qd 1 mg qd
Dolasetron 100–200 mg qd 1.8 mg/kg qd
Tropisetron 5 mg qd 5 mg qd
Palonosetron 0.5 mg qd 0.25 mg qd
NK1 receceptor antagonists
Aprepitant 125 mg qd 115 mg qd (fosaprepitant)
Casopitant 150 mg qd 90 mg qd
Corticosteroids Oral dose Intravenous dose
Dexamethasone 8 mg qd 8 mg qd
Table 2 Doses of antiemetics
when given on day 1 of pro-
phylaxis in moderately
emetogenic chemotherapy
Support Care Cancer (2011) 19 (Suppl 1):S15–S23 S17
T
ab
le
3
S
tu
di
es
(2
00
4–
20
09
)
in
1-
da
y
C
T
w
ith
th
e
ne
ur
ok
in
in
1
-r
ec
ep
to
r
an
ta
go
ni
st
s,
ap
re
pi
ta
nt
an
d
ca
so
pi
ta
nt
in
pa
tie
nt
s
re
ce
iv
in
g
M
E
C
A
ut
ho
r
D
es
ig
n
P
at
ie
nt
s
C
he
m
ot
he
ra
py
A
nt
ie
m
et
ic
s
C
R
C
R
C
R
N
o
E
E
N
o
E
E
N
o
E
E
N
o
na
us
ea
N
o
na
us
ea
N
o
na
us
ea
D
1
D
2-
5
D
1-
5
D
1
D
2-
5
D
1-
5
D
1
D
2-
5
D
1-
5
W
ar
r
20
05
[1
7]
P
ha
se
3,
ra
nd
om
iz
ed
,
do
ub
le
-b
lin
d,
tw
o-
ar
m
N
=
86
6
C
T-
na
iv
e
C
T
X
an
d
D
O
X
/E
P
I
O
nd
D
1
76
%
55
%
51
%
88
%
81
%
76
%
N
A
N
A
33
%
D
ex
D
1
A
pr
D
1-
3
or
O
nd
D
1-
3
P
=
0.
03
N
S
P
=
0.
01
5
P
<
0.
00
1
P
=
<
.0
01
P
<
0.
00
1
N
S
D
ex
D
1
69
%
49
%
42
%
77
%
69
%
59
%
33
%
Y
eo
20
09
[1
8]
P
ha
se
3,
ra
nd
om
iz
ed
,
do
ub
le
-b
lin
d,
tw
o-
ar
m
N
=
12
7
C
T-
na
iv
e
C
T
X
an
d
D
O
X
/E
P
I
O
nd
D
1
72
%
64
%
47
%
72
%
76
%
55
%
62
%
47
%
31
%
D
ex
D
1
A
pr
D
1-
3
or
O
nd
D
1-
3
N
S
N
S
N
S
N
S
N
S
N
S
N
S
N
S
N
S
D
ex
D
1
73
%
58
%
42
%
74
%
67
%
50
%
60
%
60
%
36
%
R
ap
op
or
t
20
09
[1
4]
P
ha
se
3,
ra
nd
om
iz
ed
,
do
ub
le
-b
lin
d,
tw
o-
ar
m
N
=
84
8
N
aï
ve
to
M
E
C
/H
E
C
D
if
fe
re
nt
M
E
C
O
nd
D
1
89
71
69
92
78
73
A
C
=
48
%
D
ex
D
1
N
on
-A
C
=
52
%
A
pr
D
1-
3
or
O
nd
D
1-
3
P
<
0.
00
1
P
<
0.
00
1
P
<
0.
00
1
P
<
0.
00
1
P
<
0.
00
1
P
<
0.
00
1
N
on
-A
C
=
A
R
A
-C
,
ox
al
ip
la
tin
,
ir
in
ot
ec
an
,
if
os
fa
m
id
e,
cy
ta
ra
bi
ne
ca
rb
op
la
tin
.
D
ex
D
1
80
61
56
84
67
62
G
ru
nb
er
g
20
09
[3
]
P
ha
se
2,
op
en
si
ng
le
ar
m
N
=
41
C
T-
na
ïv
e
C
T
X
an
d/
or
D
O
X
P
al
o
D
1
76
%
66
%
51
%
10
0%
95
%
95
%
59
%
41
%
32
%
A
pr
D
1
D
ex
D
1
A
pr
on
w
ir
at
20
09
[2
]
P
ha
se
2,
ra
nd
om
iz
ed
,
do
ub
le
-b
lin
d,
4-
ar
m
pl
us
2
ex
pl
or
at
or
y
ar
m
s
N
=
48
2
(4
ar
m
s)
D
if
fe
re
nt
M
E
C
C
T
X
,
do
xo
ru
bi
ci
n,
ep
ir
ub
ic
in
,
ir
in
ot
ec
an
ca
rb
op
la
tin
,
ox
al
ip
la
tin
.
A
ll
D
E
X
D
1
+
O
N
D
D
1-
3
an
d
N
=
72
3
(6
ar
m
s)
C
A
S
pl
ac
eb
o
D
1-
3
or
89
%
69
%
69
%
94
%
78
%
77
%
C
T-
na
iv
e
C
A
S
50
m
g
D
1-
3
or
92
%
81
%
81
%
95
%
90
%
88
%
C
A
S
10
0
m
g
D
1-
3
or
89
%
79
%
79
%
93
%
88
%
84
%
C
A
S
15
0
m
g
D
1-
3
or
92
%
84
%
84
%
95
%
92
%
89
%
C
A
S
15
0
m
g
D
1
on
ly
or
90
%
79
%
79
%
93
&
88
%
84
%
C
A
S
15
0
m
g
D
1-
3
93
%
84
%
84
%
96
%
93
%
90
%
N
S
P
=
0.
01
27
P
=
0.
01
27
N
S
P
<
0.
05
P
<
0.
05
H
er
rs
te
dt
20
09
[7
]
P
ha
se
3,
ra
nd
om
iz
ed
,
do
ub
le
-b
lin
d,
fo
ur
-a
rm
N
=
1,
91
7
C
T-
na
iv
e
C
T
X
an
d
D
O
X
/E
P
I
O
nd
D
1-
3
D
ex
D
1
or
85
%
59
%
59
%
86
%
63
%
63
%
71
%
35
%
35
%
O
nd
D
1-
3
D
ex
D
1
C
as
D
1
or
al
ly
or
88
%
73
%
73
%
91
%
80
%
80
%
66
%
38
%
38
%
O
nd
D
1-
3
D
ex
D
1
C
as
D
1-
3
Iv
an
d
or
al
ly
or
86
%
74
%
74
%
88
%
78
%
78
%
67
%
39
%
39
%
O
nd
D
1-
3
D
ex
D
1
C
as
D
1-
3
or
al
ly
89
%
73
%
73
%
91
%
81
%
81
%
64
%
33
%
33
%
N
S
N
A
P
<
0.
00
01
P
<
0.
05
P
<
0.
00
01
P
<
0.
00
01
N
S
N
S
N
S
A
R
A
-C
cy
ta
ra
bi
ne
,C
T
ch
em
ot
he
ra
py
,C
T
X
cy
cl
op
ho
sp
ha
m
id
e,
D
O
X
do
xo
ru
bi
ci
n,
E
P
I
ep
ir
ub
ic
in
,C
A
R
B
O
ca
rb
op
la
tin
,O
X
A
L
I
ox
al
ip
la
tin
,I
R
IN
O
ir
in
ot
ec
an
,P
al
o
pa
lo
no
se
tr
on
,D
ex
de
xa
m
et
ha
so
ne
,A
pr
ap
re
pi
ta
nt
,C
A
S
ca
si
po
ta
nt
,O
la
nz
ol
an
za
pi
ne
,
G
ra
gr
an
is
et
ro
n,
O
N
D
on
da
ns
et
ro
n,
C
R
no
em
es
is
an
d
no
re
sc
ue
m
ed
ic
at
io
n,
E
E
em
et
ic
ep
is
od
e,
D
da
y,
N
S
no
t
si
gn
if
ic
an
t,
N
A
no
t
ap
pl
ic
ab
le
S18 Support Care Cancer (2011) 19 (Suppl 1):S15–S23
that no clinically meaningful differences existed between
the agents for acute (0–24 h) efficacy and toxicity in MEC.
Since then, a number of small studies have investi-
gated palonosetron in patients receiving MEC and
different combinations of antiemetics. Because these
studies included a limited number of patients, did not
include a control arm, or used an open design, these
studies do not lead to a change in the updated guide-
lines.
Recently, a randomized, double-blind study com-
pared the antiemetic effect of granisetron plus dexa-
methasone with palonosetron plus dexamethasone in
patients receiving cisplatin-based chemotherapy
(≥50 mg/m2) or a combination of an anthracycline plus
cyclophosphamide (AC) [16]. Stratification was done for
chemotherapy, gender, and age (<55 years or ≥55 years).
The mean doses of chemotherapy were the same in the
two arms. The hypothesis was that palonosetron was
non-inferior to granisetron in the acute phase and
superior in the delayed phase for the primary endpoint
(CR=no emesis and no need for rescue antiemetics).
With a CR (0–24 h) of 75.3% versus 73.3% (p=NS) and
a CR (24–120 h) of 56.8% versus 44.5% (p<0.0001), the
hypothesis was confirmed. In the AC/EC subpopulation,
the CR rates were 69.0% versus 64.8% (0–24 h, p=NS)
and 61.1% versus 50.0% (24–120 h, p=0.0165), respec-
tively. Because guidelines recommend that aprepitant is
used in combination with a 5-HT3 receptor antagonist
plus dexamethasone in patients treated with AC chemo-
therapy, this study does not change the recommendations
for the first 24 h after initiation of AC. If a NK1 receptor
antagonist is not available, palonosetron is the preferred
5-HT3 receptor antagonist, in combination with dexa-
methasone, in patients treated with AC. A majority of the
consensus panel (70%) also agreed that palonosetron
should be the preferred 5-HT3 receptor antagonist in non-
AC MEC. These recommendations are based on the
above study and accumulating evidence from other phase
II and III studies.
Dopamine receptor antagonists
The role of dopamine receptor antagonists in the
prophylaxis of acute emesis from MEC seems to be
limited to (1) patients with refractory emesis after
previous antiemetic therapy with a combination of a 5-
HT3 receptor antagonist plus a corticosteroid or (2)
patients who are not suitable for treatment with cortico-
steroids. In the daily clinical practice, dopamine antag-
onists are also used in patients with breakthrough emesis,
but this indication has not been investigated in a
randomized trial.
Other antiemetics
These include benzodiazepines and cannabinoids. No new
studies, with an impact to change the recommendations,
have been published since 2004.
NK1 receptor antagonists
Since 2004, three phase III studies investigating aprepi-
tant [14, 17, 18] and one phase II [2] and one phase III [7]
study investigating casopitant in MEC have been pub-
lished. The results of the first phase III aprepitant study
[17] already has led to an update on the MASCC website,
recommending the addition of aprepitant to the combina-
tion of a 5-HT3-receptor antagonist plus dexamethasone in
patients receiving a combination of cyclophosphamide
plus an anthracycline. Another study with a small sample
size did not show any advantage of aprepitant in addition
to ondansetron plus dexamethasone, but given the small
sample size, this study was underpowered [18].
A recent, large phase III randomized, gender-stratified,
double-blind trial in 848 patients receiving a broad range
of MEC regimens (non-AC or AC) with a variety of
tumor types showed superiority of an aprepitant triple
regimen compared to a control regimen of ondansetron
and dexamethasone [14]. The primary efficacy endpoint
was the proportion of patients reporting no vomiting
during the 5 days (0–120 h) following initiation of
chemotherapy. Significantly more patients in the aprepi-
tant group reported no vomiting compared to the control
group 72.6% versus 62.1% (p<0.001). Also in the acute
and delayed phases, significantly more patients in the
aprepitant group reported no vomiting compared to the
control group (92% versus 83.7% (p<0.001)) and 77.9%
versus 66.8% (p<0.001), respectively. The key secondary
endpoint was the overall complete response (no emetic
episodes and no administration of rescue therapy) during
the 5 days (0–120 h) following initiation of chemother-
apy. Significantly more patients in the aprepitant group
reported complete response compared to the control
group (68.7% vs. 56.3%, p<0.001). In addition, signifi-
cantly more patients in the aprepitant group reported
complete response compared to the control group in both
the acute and delayed phases (89.2% versus 80.3%, p<
0.01 and 70.8% versus 60.9%, p<0.01), respectively. No
significant differences in the incidence of adverse events
were identified. This study confirms and reinforces the
results from the first phase III MEC study in breast cancer
patients treated with AC chemotherapy. Because the
analysis in the AC and non-AC populations were post
hoc analyses, and because of the heterogeneity of
chemotherapy in the non-AC population, this study is
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not considered sufficiently compelling to recommended
the standard use of aprepitant with the initial cycle of non-
AC chemotherapy.
Fosaprepitant is an intravenous pro-drug of aprepi-
tant. Pharmacological data have been published, but no
randomized trials using this formulation have been
published [11].
A casopitant phase II study [2] included four study
arms and two exploratory arms. Patients (n=723) were
chemotherapy-naïve and received cyclophosphamide 500–
1,500 mg/m2 if given with other MEC; cyclophosphamide
750–1,500 mg/m2 if given alone, or with agents with
minimal or low emetogenic potential; oxaliplatin≥85 mg/m2;
doxorubicin≥60 mg/m2; epirubicin≥90 mg/m2; irinotecan
or carboplatin AUC≥5. All patients received ondansetron
(days 1–3) plus dexamethasone (day 1) for antiemetic
protection. Patients were then randomized to receive, in
addition oral placebo, casopitant 50 mg, 100 mg, or
150 mg/day (days 1–3). The two exploratory arms
evaluated, respectively, a 1-day casopitant regimen
(150 mg) and a once-daily ondansetron plus casopitant
regimen. Primary endpoints were the CR rates (no
vomiting, retching, rescue therapy, or premature discon-
tinuation) and significant nausea (≥25 mm on visual
analog scale) over the first 120 h following cycle 1 of
MEC for groups 1–4. No statistics were planned on the
data from the first 24 h, but the CR rate in the control
group was 89.3%, as compared to 89.3–91.7 % in the
casopitant arms. CR rates were also comparable in the two
exploratory arms. No significant differences in the
protection from nausea were seen. Very few patients
vomited within the first 24 h after MEC (4.1–6.7%).
The casopitant phase III study [7] used a randomized,
double-blind, four-arm parallel design. Patients (n=1,933)
received cyclophosphamide IV (500-1,500 mg/m2) and
doxorubicin IV (≥40 mg/m2), or cyclophosphamide IV
(500-1,500 mg/m2), and epirubicin IV (≥60 mg/m2).
Administration of additional chemotherapy was allowed
if the additional agent(s) was of low or minimal emeto-
genic potential. All patients received dexamethasone 8 mg
IV on day 1 and oral ondansetron 8 mg twice daily on
days 1-3. Patients were randomized to a control arm
(placebo), a single oral dose casopitant arm (150 mg oral,
day 1), a 3-day oral casopitant arm (150 mg oral day 1+
50 mg orally (PO) days 2-3), or a 3-day IV/oral casopitant
arm (90 mg IV day 1+50 mg PO days 2-3). The primary
endpoint was the proportion of patients achieving
complete response (no vomiting/retching or rescue
medications) in the first 120 h after the initiation of
MEC. A significantly greater proportion of patients in the
single dose oral casopitant arm, 3-day oral casopitant
arm, and 3-day IV/oral casopitant arm achieved complete
response (73%, 73%, and 74%, respectively) versus
control (59%; p<0.0001). The study did not demonstrate
a reduced proportion of patients with nausea in those
receiving casopitant. There was no difference during the
first 24 h in the number of patients with CR. The
number of patients without vomiting was significantly
superior to the control arm (86%), as compared to the
two oral arms (91% in both, p=0.0428 and 0.0131,
respectively), but not to the iv/oral arm (88%). The single-
day oral casopitant arm was as effective as the 3-day oral
and iv/oral arms.
After the completion of the consensus conference,
GlaxoSmithKline decided to discontinue the regulatory
filings for casopitant. Consequently, casopitant cannot be
recommended by the consensus panel, but the results of the
casopitant studies contribute to the conclusions about
neurokinin1 receptor antagonists as a drug class.
Multiple cycles of MEC
The first phase III MEC study investigating the effect of
aprepitant followed patients through a maximum of four
cycles of AC chemotherapy. The aprepitant arm was
significantly superior to the control arm during all cycles
with a sustained no emesis rate of 39% versus 63% (p=
0.0001) [5].
Conclusion
Since the last consensus conference in 2004, a number of
phase II and III studies [2, 7, 14, 17, 18] have confirmed the
use of a NK1 receptor antagonist, in combination with a 5-
HT3 receptor antagonist plus dexamethasone, in patients
receiving chemotherapy, including a combination of an
anthracycline plus cyclophosphamide. There seems to be no
major differences between the NK1 receptor antagonists,
aprepitant and casopitant, although a phase III study [6]
demonstrated that casopitant can be given as a single oral
dose with the same efficacy as 3-day regimens. A small non
comparative study has however indicated that aprepitant
can also be effective, when given in a single oral dose [3].
The study by Saito et al. [16] is interesting because this
is the first time palonosetron has been compared to
granisetron in a randomized trial. The design of the study
(including both cisplatin and AC-based chemotherapy, and
the lack of a NK1 receptor antagonist in the antiemetic
regimens) limits the ability of the study to change the
recommendations in the current guidelines. Randomized
studies comparing palonosetron with another 5-HT3 recep-
tor antagonist both combined with a NK1 receptor
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antagonist and dexamethasone in the setting of cisplatin and
AC-based chemotherapy are highly warranted.
The consensus statements concerning patients receiving
moderately emetogenic chemotherapy are listed at the end of
this paper. It is indicated if a statement is new or has been
changed, as compared to the 2004 consensus document [4].
Consensus Statements 2009
Statements 1, 4, 5, 6, 7 and 9 have been changed or are new.
MASCC level of confidence and consensus defined in
Ann Oncol 1998;9:811-19.
1. Palonosetron plus dexamethasone is recommended for
prophylaxis of acute nausea and vomiting in patients,
who receive MEC not including a combination of an
anthracycline plus cyclophosphamide (changed from
2004).
MASCC level of confidence: Moderate level of consensus: Moderate
ESMO level of evidence: II grade of recommendation: B
2. A 5-HT3 receptor antagonist plus dexamethasone plus
the NK1 receptor antagonist, aprepitant is recommen-
ded for prophylaxis of acute nausea and vomiting in
patients, who receive MEC including a combination
of an anthracycline plus cyclophosphamide (un-
changed from 2004).
MASCC level of confidence: High level of consensus: High
ESMO level of evidence: I grade of recommendation: A
3. There is no difference in the effectiveness of oral or
intravenous administration of a 5-HT3 receptor antag-
onist (unchanged from 2004).
MASCC level of confidence: High level of consensus: High
ESMO level of evidence: I grade of recommendation: A
4. Recommended doses of serotonin antagonists in MEC
(changed from 2004)
The recommended oral dose of ondansetron in MEC
is 16 mg*
MASCC level of confidence: High level of consensus: High
ESMO level of evidence: I grade of recommendation: A
*Randomized studies have tested the 8 mg twice daily
schedule
The recommended intravenous dose of ondansetron
in MEC is 8 mg or 0.15 mg/kg ×1
MASCC level of confidence: Moderate level of consensus: High
ESMO level of evidence: III grade of recommendation: B
The recommended oral dose of granisetron in MEC
is 2 mg x 1.
MASCC level of confidence: High level of consensus: High
ESMO level of evidence: I grade of recommendation: A
The recommended intravenous dose of granisetron
in MEC is 1 mg or 0.01 mg/kg ×1
MASCC level of confidence: High level of consensus: High
ESMO level of evidence: I grade of recommendation: A
The recommended oral dose of dolasetron in MEC
is 100 mg ×1
MASCC level of confidence: Moderate level of consensus: High
ESMO level of evidence: II grade of recommendation: A
The recommended intravenous dose of dolasetron
in MEC is 100 mg or 1.8 mg/kg ×1
MASCC level of confidence: Moderate level of consensus: High
ESMO level of evidence: II grade of recommendation: A
The recommended oral dose of tropisetron in MEC
is 5 mg ×1
MASCC level of confidence: low level of consensus: High
ESMO level of evidence: III grade of recommendation: B
The recommended intravenous dose of tropisetron
in MEC is 5 mg ×1
MASCC level of confidence: Moderate level of consensus: High
ESMO level of evidence: III grade of recommendation: B
The recommended oral dose of palonosetron is
0.50 mg ×1 (new since 2004)
MASCC level of confidence: Moderate level of consensus:High
ESMO level of evidence: II grade of recommendation: A
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The recommended intravenous dose of palonose-
tron is 0.25 mg ×1
MASCC level of confidence: High level of consensus: High
ESMO level of evidence: I grade of recommendation: A
5. There are no clinically relevant differences in the
toxicity of the 5-HT3 receptor antagonists (unchanged
from 2004)
MASCC level of confidence: High level of consensus: High
ESMO level of evidence: I grade of recommendation: A
6. Recommended dose of dexamethasone in MEC (new
since 2004)
The recommended dose of dexamethasone admin-
istered in a two-drug combination with a 5-HT3
receptor antagonist or in a three-drug combination
with a 5-HT3 receptor antagonist and a NK1 receptor
antagonist for prophylaxis of acute nausea and
vomiting from MEC is 8 mg intravenously ×1.
MASCC level of confidence: Moderate level of consensus: High
ESMO level of evidence: II grade of recommendation: A
7. Recommended dose of neurokinin antagonists in
MEC (unchanged since 2004)
The recommended dose of oral aprepitant in the
prophylaxis of acute nausea and vomiting from MEC
is 125 mg ×1
MASCC level of confidence: Moderate level of consensus: High
ESMO level of evidence: II grade of recommendation: A
8. The recommended dose of intravenous fosaprepitant
in the prophylaxis of acute nausea and vomiting from
MEC is 115 mg ×1 (new since 2004)
MASCC level of confidence: Moderate level of consensus: High
ESMO level of evidence: II grade of recommendation: A
9. The antiemetic effect of prophylaxis with a 5-HT3
receptor antagonist plus dexamethasone declines during
multiple cycles (more than 3) of MEC (unchanged
since 2004).
MASCC level of confidence: High level of consensus: High
ASCO level of evidence: I grade of recommendation: A
10. The effect of aprepitant in patients treated with AC is
maintained during four cycles of chemotherapy (new
since 2004).
MASCC level of confidence: High level of consensus: High
ASCO level of evidence: I grade of recommendation: A
11. A dopamine antagonist can be used as supplement in
the subsequent cycles in patients who experience
nausea/emesis from MEC after treatment with stan-
dard antiemetic therapy (5-HT3 receptor antagonist
plus dexamethasone plus or minus a NK1 receptor
antagonist) (unchanged from 2004).
MASCC level of confidence: Moderate level of consensus: High
ASCO level of evidence: II grade of recommendation: B
12. A benzodiazepine can be used as supplement in the
subsequent cycles in patients who experience nausea/
emesis from MEC after treatment with standard
antiemetic therapy (5-HT3 receptor antagonist plus
dexamethasone plus or minus a NK1 receptor antag-
onist) (unchanged from 2004).
MASCC level of confidence: Moderate level of consensus: Moderate
ASCO level of evidence: II grade of recommendation: B
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